

Institutional Approval Form

Accelerating and Scaling Biological Science with AI RFA

The purpose of this form is to obtain acknowledgement of the signing institution's understanding of and agreement with CZI's requirements of grantees. This form is required to be reviewed and signed by an official authorized to sign on the applicant organization's behalf, agreeing to the requirements listed below, endorsing this application, and verifying that the information entered/uploaded into the grants portal is accurate. This signed form must be uploaded into the grant portal for the final application to be considered complete.

The policies listed below represent the values of CZI Science and give insight into the concepts that the future grant agreement will address, if the application is selected for an award. **These policies are non-negotiable** so this form should only be signed if the organization is able to comply with the terms as stated.

Questions should be directed to sciencegrants@chanzuckerberg.com.

Signature below indicates agreement to the following requirements, if grant is selected for resource-allocation award. NOTE: This grant is for an allocation of CZI's GPU resource (minimum request of 96 GPU). This is an in-kind award; there are no cash funds, financial contributions, or fees of any kind associated with the award.

Research Integrity: CZI is committed to supporting research that is reproducible and valid and scientists who are truthful. CZI does not tolerate fabrication, falsification, or plagiarism. In any case where there is reason to believe that a principal investigator or collaborator, chosen by Grantee to complete a Grant-supported project, has committed research misconduct, CZI expects Grantee to bear primary responsibility for conducting an initial inquiry and if required, a full investigation. CZI recognizes the need and duty to protect the identities of anyone who has been accused of misconduct pending investigation. However, CZI requires that Grantee notify CZI of the start and conclusion of all such investigations that involve CZI grant support. CZI will hold such information in confidence, barring any legal obligation to disclose the information. For any case for which the Grantee's investigation determines that misconduct has indeed occurred, CZI requires that the case be described in public (online), including the name(s) of any researcher(s) held responsible, or that CZI may publicly disclose such findings, including the name(s) of any researcher(s) held responsible, without restriction. In addition, Grantee shall make every

reasonable effort to inform other parties affected directly or indirectly by the misconduct, including, but not limited to, journal editors, research collaborators, and other funding, supporting, or collaborating agencies. CZI regards the National Institutes of Health Office of Research Integrity as having well defined procedures for inquiries, investigation, and publication (https://ori.hhs.gov). Grantee may follow its own standards for such inquiries so long as Grantee's procedures include a public disclosure requirement.

Ethical Conduct: CZI advocates for the highest standards of ethical conduct in research. In addition to the requirements of their own countries, principal investigators chosen by Grantee to complete a Grant-supported project shall adopt procedures for the use of animals in research, for the ethical treatment of human subjects and tissue donors, and for obtaining the written informed consent of any human subjects. CZI views the policies of the National Institutes of Health as strong models for such procedures.

Intellectual Property: CZI promotes policies that enable technologies to have the broadest reach and impact. In support of that goal, intellectual property developed under this Agreement shall be made freely available for all academic and noncommercial use. Specifically, Grant-supported projects may result in the creation of models, software and other works of authorship ("Developed Software"), data, and other intellectual property, including patentable inventions, as described further below.

Data: CZI is committed to developing and using platforms that disseminate data openly and freely. In support of these goals, any datasets and metadata either curated or generated through the Grant-supported project shall be made publicly available and easily accessible online under an Open Definition-Conformant License (preferably CCO or CC BY/CC BY SA for data that requires explicit attribution) wherever possible. Grantee agrees that CZI may host any datasets or metadata developed under this Agreement on any platform developed by CZI for such purpose. That said, CZI understands the need for subsets of data to be protected or provided with controlled access. In these cases, where necessary, data shall be handled in a controlled and proper way in accordance with national and international standards, including all privacy regulations (including, without limitation, the Health Insurance Portability and Accountability Act of 1996 and the Health Information Technology for Economic Clinical Health Act, as far as applicable). For Grant-supported projects related to the Human Cell Atlas, any raw data (sequencing, imaging, etc.) and metadata including both new measurements and newly curated existing datasets must be deposited into the Human Cell Atlas Data Coordination Platform (https://www.humancellatlas.org/data-sharing), through mechanisms and formats provided and specified by the platform developers and working groups. All software, formats, and information related to the platform can be obtained through https://github.com/HumanCellAtlas/. CZI staff will contact Grantee with further information and instructions.

Developed Software: To encourage sharing and reuse, models, code, and training data produced for new software and tools must be made available through open source licenses wherever possible. Specifically, CZI assumes code used and developed for a Grant-supported project will include some combination of newly developed code ("Developed Code"), preexisting software or code that was previously developed by Grantee ("Pre-Existing Code"), and code licensed from a third party ("Third Party Code"). All Developed Code shall be released under a permissive open-source license (e.g., MIT, BSD 2-Clause, BSD 3-Clause, or Apache v2.0) or an alternative community license supporting responsible, open scientific research (as advised by CZI), to the extent permissible and subject to any applicable CZI policies (including any applicable responsible AI guidelines or code of conduct) and legal or regulatory requirements, which in any case shall be reviewed and approved by CZI prior to release. All Pre-Existing Code, including any derivatives, shall be licensed under the most permissive license

possible given any existing licensing terms and conditions applied to such Pre-Existing Code. Grantee shall ensure that Grantee only uses or incorporates Third Party Code into the Grant-supported project that allows for further distribution (e.g., is provided under such a permissive open-source licensing program), and Grantee shall comply with the terms of the applicable licensing program. To promote open collaboration, throughout the Grant-supported project Grantee shall ensure that all code is developed in the open using a code sharing site like GitHub that will be hosted and maintained by CZI, in order to coordinate among other recipients of CZI grants, engage the community, and plan Compute. Grantee agrees that CZI may host any code, models, training data, or software developed under this Agreement on CZI's GitHub repository and any other platform developed by CZI for such purpose, and that Grantee will cooperate fully with CZI to ensure the foregoing. CZI encourages Grantee to work collaboratively with CZI and the rest of the community to ensure that the full results of the Grant-supported project are made as widely available as possible.

Patentable Inventions: In some cases, commercialization of intellectual property rights in the form of patents will provide the best route for the broadest availability and dissemination of technology arising from the Grant. Grantee's policies and procedures for intellectual property management should be followed by Grantee, and in all cases, non-exclusive patent licensing shall be given preference over exclusive licensing. All patentable and non-patentable intellectual property shall be made freely and openly available for all academic use and openly available for non-commercial use, including non-commercial use by for-profit companies. Per the foregoing requirements that all intellectual property arising from this Grant be made openly available for non-commercial use, CZI and its affiliated entities, by way of this Agreement, shall be granted a non-commercial, royalty-free, perpetual and sublicensable license to all intellectual property arising from the Grant.

Reagent Sharing: Grantees shall make all data and replicable materials available, in a timely manner, from the date of publication. CZI encourages the use of existing community repositories where possible (e.g., Jackson Labs, the Drosophila Stock Center at Bloomington, the Developmental Studies Hybridoma Bank, Addgene). The requirement for sharing applies to clones, and to transgenic organisms and cell lines (including monoclonal antibodies), as applicable.

Publication: CZI supports full publication and public availability of research findings without conditions or restrictions on academic and publication freedom. Grantee shall submit all manuscripts for any publications that were supported in whole or in part by the Grant as preprints to bioRxiv, or a similar service for sharing preprints, before or upon first submission to a journal. Grantee shall make experimental protocols publicly available through a protocol sharing service such as https://protocols.io. Grantee may contact CZI staff if there is some reason that will make this impossible or counterproductive. Grantee shall notify CZI regarding all publications submitted or published as part of the annual report. CZI advocates for and supports open access, such as is outlined in the 2012 San Francisco Declaration of Research Assessment (http://www.ascb.org/dora/). Acknowledgements of support will be included in publications referencing research supported under the Grant.

No Indirect Costs: Grantee acknowledges and agrees that there will be no overhead fee, gift charge, infrastructure fee, operations fee, administrative fee, indirect cost rate, or other similar charge or fee assessed for the Grant.

Tax Status: This Grant is subject to the condition that Grantee:

- (i) is recognized by the Internal Revenue Service as an organization described in Section 501(c)(3) of the United States Internal Revenue Code (the "Code") which is not a private foundation because it is described in Sections 509(a)(1), 509(a)(2), or 509(a)(3) of the Code, and (ii) is operated for tax-exempt purposes described in Section 501(c)(3) of the Code; or
- (ii) is recognized by the Internal Revenue Service as an organization that is a state instrumentality under Section 170(c)(1) of the Code and a public organization described in Section 53.4945-5(a)(4)(ii) of the U.S. Treasury Regulations, and (ii) will utilize the grant for exclusively charitable public purposes described in Section 501(c)(3) of the Code.

APPLICANT ORGANIZATION CERTIFICATION: Executed by a person authorized to sign on behalf of the applicant organization.

I certify that the statements herein are true, complete, and accurate to the best of my knowledge, and accept the obligation to comply with CZI requirements listed above if a grant is recommended for a resource allocation award as a result of this application.

Name:	
Title:	
Signature:	Date: